Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IL2 | P60568 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180886 | 0.85 | KDM4E (0.50) | KDM4EHRH3LMNAHTTMAPT | |
| SCHEMBL1621903 | 0.85 | KDM4E (0.50) | KDM4EHRH3LMNAHTTMAPT | |
| SCHEMBL471881 | 0.79 | KDM4E (0.62) | KDM4EHRH3LMNAHTTMAPT | |
| SCHEMBL5165520 | 0.79 | HPGD (0.45) | KDM4EHRH3LMNAHTTMAPT | |
| SCHEMBL20410843 | 0.76 | KDM4E (0.59) | KDM4EHRH3LMNAHTTMAPT | |
| SCHEMBL4748328 | 0.75 | KDM4E (0.54) | KDM4EHRH3LMNAHTTMAPT | |
| SCHEMBL1624547 | 0.75 | KDM4E (0.54) | KDM4EHRH3LMNAHTTMAPT | |
| SCHEMBL30863841 | 0.73 | KDM4E (0.56) | KDM4EHRH3LMNAHTTMAPT | |
| SCHEMBL1338857 | 0.73 | KDM4E (0.56) | KDM4EHRH3LMNAHTTMAPT | |
| SCHEMBL5163951 | 0.72 | KDM4E (0.51) | KDM4EHRH3LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | BPGM, HRH1, HRH3 | KDM4E 4785/4885HRH3 3/4885LMNA 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.